Inveniv

Aaron Mazze, Principal and Founder

That is no longer the case. The AI capabilities now built into mainstream marketing and CRM platforms can be configured by the people who already run campaigns, manage accounts and support customers. The learning curve has not disappeared, but it has flattened enough that a small team can put sophisticated AI to work without a major technology initiative.

For life sciences organizations, the timing matters. Buying cycles are long, and technical, scientific, financial and procurement stakeholders all shape the decision. The first conversation now often happens before a buyer ever contacts a sales representative, whether through a search engine, an AI assistant, industry research or a colleague's recommendation.

Accessible AI gives marketing, sales and operations teams new ways to see that earlier activity, understand it and act on it. The shift is from reacting to inbound requests to anticipating what the market needs next.

Decoding Buyer Intent through Digital Signals

Most website visitors never identify themselves. Buyer intent tools help organizations understand which companies are visiting their websites, which content is attracting attention and which topics signal interest.

For a CDMO, knowing that several emerging biotech companies have spent time on its fill-finish or analytical development content could change the next sales conversation. Aggregated over time, these signals also show where market interest is building.

But individual signals aren't the answer on their own. Context is what makes them valuable. Knowing that a company visited a particular webpage is useful; combining that activity with the company's pipeline, modalities, clinical stage, funding, corporate developments, existing relationships and previous engagement tells a much richer story.

We're no longer simply asking, "Who visited our website?" We're asking, "Why might this company be interested in us right now?" That is a far more valuable commercial question.

AI Agents That Assess Fit before the First Call

This is where we are investing most at Inveniv. We are building and testing AI agents that assess prospective organizations across multiple dimensions at once:

• Technical fit: capabilities, modalities and platforms
• Molecular and indication fit: therapeutic areas, targets and programs in development
• Financial position: recent funding, partnerships and other financial signals
• Relationship connections: existing contacts, shared partners and prior engagement
• Current activity: news, regulatory milestones, pipeline progress and other meaningful developments

Research that once required hours of manual investigation can now be assembled and assessed in minutes. More importantly, these agents bring together information that would otherwise live in separate systems or require multiple searches, giving commercial teams a more complete picture of an organization before deciding whether, and how, to engage.

Being Found in AI Answers, Not Just Search Results

At the same time, the way customers discover life sciences companies is changing. Prospective customers now ask AI assistants for technical explanations, potential solutions and companies that may be able to help them. That raises a new question for marketers: when someone asks an AI platform about the problem we solve, what does it say and are we part of the answer?

Answer engine optimization, or AEO, has emerged around this challenge. New tools show how often an organization appears in AI-generated answers, which sources are cited, how it compares with competitors and where information gaps exist. They also identify content opportunities that improve the information available to both prospective customers and the AI systems assisting them.

This creates a different feedback loop for marketing. Instead of only asking which keywords generate traffic, we can examine the questions customers are asking, the topics gaining attention and whether we provide enough authoritative information for AI systems to understand and accurately represent our expertise.

One Website, Two Audiences

This is also prompting many life sciences organizations to rethink their websites. A modern website serves two audiences with different needs: the humans evaluating an organization and the AI systems helping them research it.

For AI, that means structured data, clearly defined services, deeper technical information, authoritative content and an information architecture that helps machines understand the relationships between capabilities, products, technologies and areas of expertise.

For people, it's an opportunity to create something very different from the traditional corporate website. Interactive tools, guided pathways, personalization, video and visualization can make complex science and services easier, and more interesting, to explore.

The two goals aren't in conflict. The experience for humans can become more interactive and engaging while the information behind it becomes richer, and the clarity that helps an AI system understand an organization also helps a prospective customer understand it faster. For life sciences companies, whose websites must speak to scientists, procurement teams, investors, partners, patients and prospective employees, that is an important evolution in digital strategy.

Customer Agents that Listen

AI can also change what happens once someone arrives. Customer-facing agents can answer questions around the clock using an organization's own knowledge base, technical documentation and other approved information. For a CRO fielding capability questions or a reagent supplier handling specification requests, that means faster, more consistent responses without anyone searching through dozens of pages.

The value goes beyond speed. Every question becomes a signal about what customers need, where information is missing and which topics are generating interest. When an inquiry requires scientific judgment or a human conversation, the agent escalates it with the context that led to the interaction intact.

The objective isn't to remove people from the customer experience. It's to make the conversation between people more informed when it happens.

From Reactive to Proactive

Taken together, these capabilities change the rhythm of commercial work. Marketing can identify topics gaining attention earlier. Sales can enter conversations with a deeper understanding of a prospect's pipeline, funding, capabilities and connections. Operations can recognize patterns in customer questions that expose information or service gaps. The result can be a shorter sales cycle and a clearer view of what the market actually needs.

None of this removes the need for human judgment. Life sciences communication has to remain accurate, and AI output involving scientific, technical or regulated information requires appropriate governance and expert review. The organizations getting the most from these tools will treat AI as a way to see further and move sooner, while people remain responsible for the decisions that matter.

Not long ago, building systems that could research a company, interpret its pipeline, evaluate technical fit and bring that intelligence into a commercial workflow would have been a significant software development initiative. Today, marketers can build and manage these capabilities themselves. Organizations still need good data, thoughtful strategy and governance, but the technical barrier is falling quickly.

The real opportunity isn't doing the same work faster. It's understanding customers, prospects and markets sooner. The question for life sciences leaders is no longer whether their teams can use these tools, but how quickly they can start learning from them.